iOnctura

4 known investors

Ionctura develops therapies targeting the tumor-stroma-immune interface to treat hard-to-treat and neglected cancers with improved efficacy and lower toxicity than conventional treatments. The company's pipeline includes small molecule modulators and inhibitors addressing dysregulated signaling pathways in cancer.